BRPI0619428B1 - processo para a síntese de 17a-cianometil-17ß-hidroxiestra-4,9-dieno-3-ona - Google Patents
processo para a síntese de 17a-cianometil-17ß-hidroxiestra-4,9-dieno-3-ona Download PDFInfo
- Publication number
- BRPI0619428B1 BRPI0619428B1 BRPI0619428-1A BRPI0619428A BRPI0619428B1 BR PI0619428 B1 BRPI0619428 B1 BR PI0619428B1 BR PI0619428 A BRPI0619428 A BR PI0619428A BR PI0619428 B1 BRPI0619428 B1 BR PI0619428B1
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- process according
- dienogest
- diene
- hydroxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 21
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 20
- 229960003309 dienogest Drugs 0.000 claims abstract description 45
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims abstract description 39
- OFIPMSSTKFSADG-UHFFFAOYSA-N [Li]CC#N Chemical compound [Li]CC#N OFIPMSSTKFSADG-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000002953 preparative HPLC Methods 0.000 claims description 7
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- 238000006215 cyanomethylation reaction Methods 0.000 claims description 3
- CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000004135 Bone phosphate Substances 0.000 claims 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 15
- 238000001514 detection method Methods 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- XFFZLECPCHQJIR-BBCBXFPWSA-N (8r,9s,13s,14s)-3-methoxy-13-methyl-1,4,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-ol Chemical compound C1C[C@@H]2C(CC=C(C3)OC)=C3CC[C@H]2[C@@H]2CCC(O)[C@]21C XFFZLECPCHQJIR-BBCBXFPWSA-N 0.000 abstract description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- NSUVCVKCWGOYPV-VXNCWWDNSA-N (8r,9s,13s,14s)-3-methoxy-13-methyl-4,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-one Chemical compound C1C[C@@H]2C(CC=C(C3)OC)=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C NSUVCVKCWGOYPV-VXNCWWDNSA-N 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- LMHHRCOWPQNFTF-UHFFFAOYSA-N s-propan-2-yl azepane-1-carbothioate Chemical compound CC(C)SC(=O)N1CCCCCC1 LMHHRCOWPQNFTF-UHFFFAOYSA-N 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007858 starting material Substances 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- -1 alkali metal cyanide Chemical class 0.000 description 4
- GZRYBYIBLHMWCD-UHFFFAOYSA-N dimethyl(methylidene)-$l^{4}-sulfane Chemical compound CS(C)=C GZRYBYIBLHMWCD-UHFFFAOYSA-N 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000006036 Oppenauer oxidation reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HWDHOPWPLHWQGF-BBCBXFPWSA-N (8r,9s,13s,14s)-3,3-dimethoxy-13-methyl-2,4,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-ol Chemical compound C1C[C@@H]2C(CCC(C3)(OC)OC)=C3CC[C@H]2[C@@H]2CCC(O)[C@]21C HWDHOPWPLHWQGF-BBCBXFPWSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001230030 Nossa Species 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007269 dehydrobromination reaction Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002924 oxiranes Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Abstract
Description
i) o 3-metoxi-17-hidroxi-estra-2,5(10)-dieno da fórmula (V) é reagido com isopropilato de alumínio na presença de ciclohexanona em um solvente orgânico inerte sob aquecimento
ii) O 3-metoxi-estra-2,5(10)-dieno-17-ona da fórmula (IV)assim obtido é reagido com cianometil lítio a uma temperatura entre 0°C e -30°C,
iii) o 3-metoxi-17α-cianometil-17β-hidroxi-estra-2,5(10)-dieno da fórmula (III)obtido é reagido com um ácido orgânico forte em solução de tetrahidrofurano,
iv) O 17α-cianometil-17β-hidroxi-estr-5(10)-eno-3-ona da fórmula (III)obtido é reagido com 1 a 1,5 equivalente de tribrometo de piridínio em solução de piridina a uma temperatura entre 0°C e 60°C, então o dienogest cru obtido, da fórmula (I), é purificado por recristalização e HPLC preparativo.
- - a síntese pode ser executada em escala industrial, aumentando o tamanho do lote se comparado ao tamanho descrito nos Exemplos e não provoca problemas técnicos e não influencia a pureza do produto final,
- - o material inicial da síntese, o 3-metoxi-17-hidroxi-estra-2,5(10)-dieno da fórmula (V), é um produto industrial facilmente acessível,
- - a síntese consiste de menos etapas de reação -apenas 4 - que o processo conhecido na literatura - 5, 6 e 8 etapas,
- - utilizar as condições de reação de acordo com nossa invenção torna os rendimentos das etapas de reação da síntese muito maiores que os rendimentos proporcionados no estado da técnica. O rendimento de cada etapa é superior a 80%, portanto o rendimento total é superior a 50%.
- - a qualidade do dienogest de alta pureza sintetizado é melhor que as exigências de qualidade da farmacopéia. A quantidade de impurezas é determinada por HPLC. De acordo com estas verificações em nosso produto, a quantidade total de impurezas é inferior a 0,1% e a quantidade de 4-bromo-dienogest, que é uma impureza detectável nas composições farmacêuticas comercializadas em mais de 0,1%, está abaixo do limite de detecção (0,02%).
- - na reação de cianometilação os cianetos alcalinos e os derivados de dimetilsulfônio são utilizados, de acordo com as regulamentações ambientais e considerações econômicas, assim como o butil lítio, perigoso e caro, também não é utilizado - uma solução de hexano, de hexil lítio, é utilizada ao invés dos anteriores.
Pureza: min. de 98% (HPLC).
Ponto de fusão: 106°C a 110°C.
Pureza: min. de 98% (HPLC).
Ponto de fusão: 145°C a 150°C.
Pureza: min. de 98% (HPLC).
Ponto de fusão: 170°C a 175°C.
Quantidade de ingrediente ativo: min. 97% (HPLC).
Impureza 4-bromo-dienogest: máx. 1 % (HPLC).
Ponto de fusão: 210°C a 213°C.
[a]20D = -318° (c = 1%, diclorometano).
Quantidade total de impurezas: máximo de 0,1% (HPLC).
Impurezas individuais: máximo de 0,02% (HPLC).
Ponto de fusão: 211°C a 214°C.
[a]20D = -322° (c = 1%, diclorometano).
Quantidade total de impurezas: máximo de 0,1% (HPLC).
Impurezas individuais: máximo de 0,02% (HPLC).
Ponto de fusão: 211°C a 214°C.
[a]20D = -322° (c = 1%, diclorometano).
Quantidade total de impurezas: máximo de 0,1% (HPLC).
Impurezas individuais: máximo de 0,02% (HPLC).
Ponto de fusão: 211°C a 214°C.
[a]20D = -322° (c = 1%, diclorometano).
Claims (14)
- Processo para a síntese de 17α-cianometil-17β-hidroxi-estra-4,9-dieno-3-ona (posteriormente em dienogest) da fórmula (I):a partir de 3-metoxi-17-hidroxi-estra-2,5(10)-dieno da fórmula (V):caracterizado por
i) reagir o 3-metoxi-17-hidroxi-estra-2,5(10)-dieno da fórmula (V) com isopropilato de alumínio na presença de ciclohexanona em um solvente orgânico inerte sob aquecimento ;
ii) reagir o então obtido 3-metoxi-estra-2,5(10)-dieno-17-ona da fórmula (IV):com cianometil lítio a uma temperatura entre 0°C e - 30°C;
iii) reagir então, o obtido 3-metoxi-17α-cianometil17β-hidroxi-estra-2,5(10)-dieno da fórmula (III):obtido com um ácido orgânico forte em solução de tetrahidrofurano;
iv) reagir o 17α-cianometil-17β-hidroxi-estr-5(10)-eno-3-ona da fórmula (II) obtido:com 1 a 1,5 equivalente de tribrometo de piridínio em solução de piridina a uma temperatura entre 0°C e 60°C;
e então, purificar o dienogest cru obtido da fórmula (I) por recristalização e HPLC preparativo. - Processo, de acordo com a reivindicação 1, caracterizado por realizar a etapa de oxidação i) em tolueno na presença de 20 a 25 equivalentes de ciclohexanona entre 100°C e 120°C.
- Processo, de acordo com a reivindicação 1 ou 2, caracterizado por a preparação do reagente de cianometil lítio da etapa ii) ser in situ a partir de hexil lítio e acetonitrila.
- Processo, de acordo com qualquer uma das reivindicações 1 a 3, caracterizado por realizar a reação de cianometilação da etapa ii) entre 0°C e -30°C.
- Processo, de acordo com qualquer uma das reivindicações 1 a 4, caracterizado por realizar a reação de cianometilação da etapa ii) entre -10°C e -20°C.
- Processo, de acordo com qualquer uma das reivindicações 1 a 5, caracterizado por utilizar 2 equivalentes de reagente cianometil lítio na etapa ii).
- Processo, de acordo com qualquer uma das reivindicações 1 a 6, caracterizado por realizar o tratamento ácido da etapa iii) com um ácido orgânico di ou tribásico em tetrahidrofurano.
- Processo, de acordo com qualquer uma das reivindicações 1 a 7, caracterizado por realizar o tratamento ácido da etapa iii) com 2 equivalentes de dihidrato de ácido oxálico.
- Processo, de acordo com qualquer uma das reivindicações 1 a 8, caracterizado por reagir o composto da fórmula (II) com 1,05 equivalente de tribrometo de piridínio na etapa iv).
- Processo, de acordo com qualquer uma das reivindicações 1 a 9, caracterizado por reagir o composto da fórmula (II) com tribrometo de piridínio entre 0°C e 60°C na etapa iv).
- Processo, de acordo com qualquer uma das reivindicações 1 a 10, caracterizado por reagir o composto da fórmula (II) com tribrometo de piridínio entre 25°C e 50°C.
- Processo, de acordo com qualquer uma das reivindicações 1 a 11, caracterizado por purificar o dienogest da fórmula (I) por HPLC utilizando sílica gel como adsorvente.
- Processo, de acordo com qualquer uma das reivindicações 1 a 12, caracterizado por purificar o dienogest da fórmula (I) por HPLC utilizando as seguintes misturas de solvente como eluentes: 70:30 de diclorometano/acetato de etila ou 80:20 de diclorometano/tercbutil metil éter ou 90:10 de diclorometano/acetona.
- Processo, de acordo com qualquer uma das reivindicações 1 a 13, caracterizado por recristalizar o dienogest da fórmula (I) obtido por HPLC preparativo a partir de acetato de etila, acetona, tertbutil metil éter, éter diisopropílico, acetonitrila, metanol, etanol ou mistura aquosa de diferentes proporções destes solventes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP0501132 | 2005-12-05 | ||
HU0501132A HUP0501132A2 (en) | 2005-12-05 | 2005-12-05 | 17-alpha-cyanomethyl-17betha-hydroxyestra-4,9-diene-3-one of high purity and process for its production |
PCT/HU2006/000091 WO2007066158A2 (en) | 2005-12-05 | 2006-10-11 | HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0619428A2 BRPI0619428A2 (pt) | 2011-10-04 |
BRPI0619428B1 true BRPI0619428B1 (pt) | 2021-02-17 |
BRPI0619428B8 BRPI0619428B8 (pt) | 2021-05-25 |
Family
ID=89986433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0619428A BRPI0619428B8 (pt) | 2005-12-05 | 2006-10-11 | processo para a síntese de 17a-cianometil-17ß-hidroxiestra-4,9-dieno-3-ona |
Country Status (22)
Country | Link |
---|---|
US (1) | US8314145B2 (pt) |
EP (1) | EP1963354B1 (pt) |
JP (1) | JP5399711B2 (pt) |
CN (1) | CN101360757B (pt) |
AT (1) | ATE451383T1 (pt) |
AU (1) | AU2006323005B2 (pt) |
BR (1) | BRPI0619428B8 (pt) |
CA (1) | CA2631748C (pt) |
CY (1) | CY1110063T1 (pt) |
DE (1) | DE602006011052D1 (pt) |
DK (1) | DK1963354T3 (pt) |
EA (1) | EA014558B1 (pt) |
ES (1) | ES2338047T3 (pt) |
HR (1) | HRP20100102T1 (pt) |
HU (1) | HUP0501132A2 (pt) |
IL (1) | IL191915A (pt) |
MX (1) | MX2008007243A (pt) |
PL (1) | PL1963354T3 (pt) |
PT (1) | PT1963354E (pt) |
SI (1) | SI1963354T1 (pt) |
UA (1) | UA91390C2 (pt) |
WO (1) | WO2007066158A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE536362T1 (de) | 2009-05-22 | 2011-12-15 | Heyl Chem Pharm | Verfahren zur synthese von dienogest aus estron-3-methylether |
EP2560984B1 (en) | 2010-04-20 | 2015-04-01 | Lupin Limited | Process for the preparation of dienogest substantially free of impurities |
CN101863947A (zh) * | 2010-06-29 | 2010-10-20 | 沈阳药科大学 | 一种地诺孕素的合成方法 |
CN103304619B (zh) * | 2013-06-08 | 2015-12-02 | 西藏海思科药业集团股份有限公司 | 一种地诺孕素化合物 |
HU230788B1 (en) * | 2013-12-16 | 2018-05-02 | Richter Gedeon Nyrt | Norsteroid intermediates and process for their preparation |
WO2017064814A1 (ja) * | 2015-10-16 | 2017-04-20 | 持田製薬株式会社 | ジエノゲスト含有錠剤 |
JP6002870B1 (ja) * | 2015-10-16 | 2016-10-05 | 持田製薬株式会社 | 低用量薬物を含有する口腔内崩壊錠 |
CN110357937A (zh) * | 2018-03-26 | 2019-10-22 | 华润紫竹药业有限公司 | 一种地诺孕素化合物 |
CN110655551A (zh) * | 2019-09-23 | 2020-01-07 | 华润紫竹药业有限公司 | 一种地诺孕素药物单一新晶型及其制备方法 |
CN114736261A (zh) * | 2022-05-17 | 2022-07-12 | 梯尔希(南京)药物研发有限公司 | 8,11-二烯地塞米松的合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3391165A (en) * | 1966-04-07 | 1968-07-02 | Smith | Synthesis of gon-5(10)-enes |
DE2718872A1 (de) * | 1976-06-14 | 1977-12-22 | Jenapharm Veb | Verfahren zur herstellung von neuen gona-4,9(10)-dienen |
DD160418A1 (de) * | 1979-05-22 | 1983-07-27 | Kurt Ponsold | Verfahren zur herstellung von 17alpha-substituierten gona-4,9-dienen |
US5438134A (en) * | 1990-07-09 | 1995-08-01 | Jenapharm Gmbh | Process for the production of unsaturated 17 α-cyanomethyl-17 β-h |
IL119649A (en) | 1995-11-30 | 2002-03-10 | Akzo Nobel Nv | Preparation of Cyclic Kills of History - 3 keto- (5) 10, (-9) 11 steroidadians |
IT1318491B1 (it) * | 2000-04-21 | 2003-08-25 | Ind Chimica Srl | Processo per la preparazione di un precursore di tibolone e diestradiol derivati strutturalmente correlati. |
JP5230450B2 (ja) * | 2006-02-17 | 2013-07-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | プロゲステロン受容体モジュレーターとして有用な17−燐ステロイド誘導体 |
-
2005
- 2005-12-05 HU HU0501132A patent/HUP0501132A2/hu unknown
-
2006
- 2006-10-11 US US12/096,209 patent/US8314145B2/en active Active
- 2006-10-11 MX MX2008007243A patent/MX2008007243A/es active IP Right Grant
- 2006-10-11 AU AU2006323005A patent/AU2006323005B2/en active Active
- 2006-10-11 CN CN2006800515980A patent/CN101360757B/zh active Active
- 2006-10-11 ES ES06808800T patent/ES2338047T3/es active Active
- 2006-10-11 PL PL06808800T patent/PL1963354T3/pl unknown
- 2006-10-11 DK DK06808800.4T patent/DK1963354T3/da active
- 2006-10-11 UA UAA200808851A patent/UA91390C2/ru unknown
- 2006-10-11 JP JP2008543921A patent/JP5399711B2/ja active Active
- 2006-10-11 EP EP06808800A patent/EP1963354B1/en active Active
- 2006-10-11 AT AT06808800T patent/ATE451383T1/de active
- 2006-10-11 BR BRPI0619428A patent/BRPI0619428B8/pt active IP Right Grant
- 2006-10-11 WO PCT/HU2006/000091 patent/WO2007066158A2/en active Application Filing
- 2006-10-11 CA CA2631748A patent/CA2631748C/en active Active
- 2006-10-11 SI SI200630561T patent/SI1963354T1/sl unknown
- 2006-10-11 DE DE602006011052T patent/DE602006011052D1/de active Active
- 2006-10-11 EA EA200801508A patent/EA014558B1/ru unknown
- 2006-10-11 PT PT06808800T patent/PT1963354E/pt unknown
-
2008
- 2008-06-03 IL IL191915A patent/IL191915A/en active IP Right Grant
-
2010
- 2010-01-29 CY CY20101100088T patent/CY1110063T1/el unknown
- 2010-02-26 HR HR20100102T patent/HRP20100102T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006323005A1 (en) | 2007-06-14 |
JP5399711B2 (ja) | 2014-01-29 |
ATE451383T1 (de) | 2009-12-15 |
SI1963354T1 (sl) | 2010-03-31 |
BRPI0619428A2 (pt) | 2011-10-04 |
IL191915A0 (en) | 2008-12-29 |
MX2008007243A (es) | 2008-10-22 |
BRPI0619428B8 (pt) | 2021-05-25 |
WO2007066158A2 (en) | 2007-06-14 |
PL1963354T3 (pl) | 2010-05-31 |
IL191915A (en) | 2016-04-21 |
HUP0501132A2 (en) | 2007-06-28 |
DE602006011052D1 (de) | 2010-01-21 |
CA2631748C (en) | 2013-12-03 |
CN101360757B (zh) | 2011-07-20 |
CN101360757A (zh) | 2009-02-04 |
PT1963354E (pt) | 2010-01-06 |
CA2631748A1 (en) | 2007-06-14 |
CY1110063T1 (el) | 2015-01-14 |
JP2009518377A (ja) | 2009-05-07 |
HU0501132D0 (en) | 2006-01-30 |
AU2006323005B2 (en) | 2013-05-30 |
EP1963354B1 (en) | 2009-12-09 |
EP1963354A2 (en) | 2008-09-03 |
UA91390C2 (en) | 2010-07-26 |
US20080287404A1 (en) | 2008-11-20 |
EA014558B1 (ru) | 2010-12-30 |
EA200801508A1 (ru) | 2008-10-30 |
HRP20100102T1 (hr) | 2010-04-30 |
US8314145B2 (en) | 2012-11-20 |
WO2007066158A3 (en) | 2007-08-09 |
DK1963354T3 (da) | 2010-04-12 |
ES2338047T3 (es) | 2010-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0619428B1 (pt) | processo para a síntese de 17a-cianometil-17ß-hidroxiestra-4,9-dieno-3-ona | |
NL193616C (nl) | Gesubstitueerde androsta-1,4-dieen-3,17-dionen, alsmede farmaceutische preparaten die dergelijke verbindingen bevatten. | |
JP3977462B2 (ja) | 11−(置換フェニル)−エストラ−4,9−ジエン誘導体 | |
AU2007298770B2 (en) | Processes for the preparation of ciclesonide and its crystal form | |
JPH0826062B2 (ja) | 9―α―ヒドロキシステロイド及びその製法 | |
EP2367808A2 (en) | PROGESTATIONAL 3-(6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-ENE-17a-YL) PROPIONIC ACID g-LACTONES | |
JP4971179B2 (ja) | 17−ヒドロキシ−6β,7β;15β,16β−ビスメチレン−3−オキソ−17α−プレグネ−4−エン−21−カルボン酸γ−ラクトンの工業的製造方法およびこの方法のための重要中間体 | |
PT1831239E (pt) | Processo para a preparação de γ-lactona do ácido 17- hidroxi-6β, 7β; 15β, 16β-bismetileno-17α- pregn-4-eno-3- ona-21 carboxílico e intermediários chave para este processo | |
EP0347370A2 (de) | 10beta, 11beta-überbrückte Steroide | |
HUT64362A (en) | Process for producing 9-alpha-hydroxy-11-beta-bridged steroides and pharmaceutical preparatives containing said compounds | |
JPS5931800A (ja) | 19−チオ−アンドロスタン誘導体 | |
JPS62158300A (ja) | 10β−アルキニルエストレン誘導体およびそれらの製造法 | |
JP2003508541A (ja) | 11位に炭化水素置換基を有する非芳香族エストロゲンステロイド | |
US4427592A (en) | Androstene-17-dithioketals | |
EP0058097A2 (fr) | Nouveau procédé de préparation de 17alpha-hydroxy 17bêta-hydroxyacétyl stéroides et produits intermédiaires correspondants obtenus | |
WO2012020417A1 (en) | Process for the preparation of estradiol and its derivatives | |
ES2226949T3 (es) | 14,15-ciclopropano-androstanos insaturados, un procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
JP2557308B2 (ja) | 新規なアンドロステンジオン誘導体 | |
EP0071178B1 (en) | Acyloxysteroids and process for producing same | |
JP2002241395A (ja) | エストラ−4,6−ジエン−3,17−ジオンの製造方法 | |
JPS6222998B2 (pt) | ||
HUT75517A (en) | New synthesis of 17beta-cyano-3-ethoxy-17alfa-hydroxy-6-methylandrosta-3,5,9(11)-triene and its -17-one intermediate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/02/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/10/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |